Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...
Business Wire4d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...
Yahoo Finance21d
Here’s Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing
In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other stocks. One of the strongest stock market anomalies is the momentum ...
Nasdaq4d
Scholar Rock Names Lisa Wyman As Chief Technical And Quality Officer
(RTTNews) - Scholar Rock (SRRK), a late-stage biopharmaceutical company developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, Wednesday announced the appointment ...
Morningstar4d
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
She joins Scholar Rock’s Executive Team ... she had roles of increasing responsibility at Mersana Therapeutics, Shire, and Boston Scientific. She graduated from Ithaca College with a degree ...
Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts
Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have received an average recommendation of “Buy” from the ...
Hosted on MSN28d
SA Asks: Which biotechs are most likely to be acquired near-term?
Sarepta Therapeutics (NASDAQ ... Huntington’s disease candidate advances towards potential FDA approval; Scholar Rock (NASDAQ:SRRK), which has a late-stage spinal muscular atrophy drug and ...